PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsAlzheimer disease
MeSH D000544 - alzheimer disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D003704:Dementia
$
Success rate
D024801:Tauopathies
0 Companies
0 Drugs
Success rate
D000544: 
Alzheimer disease
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
1 A PharmaRivastigmine Rivastigmine 1 A Pharma  2009-12-11   
3MRivastigmine Rivastigmine 3M Health Care Ltd  2014-04-03   
AbbVieMemantine Namenda  2003-10-16   
Memantine, Donepezil Namzaric 2025-11-22 2014-12-23   
Valproic acid Depakene  1982-01-01   
Accord HealthcareDonepezil Donepezil  2011-08-29   
Memantine Memantine Accord  2013-12-03   
ACME LaboratoriesMemantine Memantine  2018-05-07   
Ajanta PharmaMemantine Memantine  2015-11-30   
Alembic PharmaceuticalsDonepezil Donepezil  2013-02-25   
Memantine Memantine  2015-10-13   
Rivastigmine Rivastigmine  2012-06-12   
AllerganMemantine Namenda  2005-04-18 $16.2 M Q2/19-Q1/20 
Donepezil Donepezil  2015-12-17   
Galantamine Galantamine  2008-12-15   
Memantine Nemdatine  2013-04-22   
Rivastigmine Rivastigmine  2008-01-08   
Rivastigmine Rivastigmine Actavis  2011-06-16   
AlvogenRivastigmine Rivastigmine  2015-08-31   
Amneal PharmaceuticalsMemantine Memantine  2015-04-10   
Memantine, Donepezil Memantine Donepezil  2017-01-27   
Rivastigmine Rivastigmine  2019-01-08   
1
2
3
4
5
6
...
9
>
Clinical Trials
Historical Success Rate
Phase 1
64%
74/115
Phase 2
45%
71/159
Phase 3
33%
42/126
Approved: 12Overall Success rate: 10%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
AbbVie
Allergan
1
2
3
4
5
6
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use